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Background: Many receptors function by binding to multiple ligands, each eliciting a distinct biological output.
The extracellular domain of the human prolactin receptor (hPRL-R) uses an identical epitope to bind to both
prolactin (hPRL) and growth hormone (hGH), yet little is known about how each hormone binding event triggers
the appropriate response.
Findings: Here, we utilized a phage display library to generate synthetic antibodies (sABs) that preferentially
modulate hPRL-R function in a hormone-dependent fashion. We determined the crystal structure of a sAB-hPRL-R
complex, which revealed a novel allosteric mechanism of antagonism, whereby the sAB traps the receptor in a
conformation more suitable for hGH binding than hPRL. This was validated by examining the effect of the sABs on
hormone internalization via the hPRL-R and its downstream signaling pathway.
Conclusions: The findings suggest that subtle structural changes in the extracellular domain of hPRL-R induced by
each hormone determine the biological output triggered by hormone binding. We conclude that sABs generated
by phage display selection can detect these subtle structural differences, and therefore can be used to dissect the
structural basis of receptor-ligand specificity.
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It is commonplace for a single receptor to recognize a
number of different ligands and a single ligand to bind
to a number of different receptors [1]. In many cases,
the distinct biological output elicited by each ligand is
due to its interaction with a different epitope on the
surface of a receptor, triggering a defined signaling
pathway. In some unique cases, a receptor is able to
interact with different ligands using an identical set of
amino acids, yet each ligand results in a distinct biological
outcome.
A prominent example of this type of promiscuity is
the prolactin receptor (PRL-R), which uses the same set
of amino acids on its extracellular domain (ECD) to
bind to two different hormones: prolactin (PRL) [2,3]
and growth hormone (GH) [4,5]. Prolactin receptor* Correspondence: koss@bsd.uchicago.edu
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unless otherwise stated.signaling is primarily triggered by homodimerization
[3], which is induced by GH or PRL binding. Since the
structures of hGH and PRL contain no tertiary symmetry,
in forming their respective complexes with the ECD
homodimers, the hormones employ opposite faces utiliz-
ing surface epitopes possessing quite different topograph-
ical and electrostatic features [4-6]. As a consequence, in
the case for both PRL and GH, the ECD binding sites have
quite different affinities: a high affinity site called Site 1,
and a lower affinity site, Site2 [6]. Although Site1 has
higher affinity than Site2, quite remarkably, the paratope
they interact with on the ECD is virtually identical. Thus,
the same binding patch on the PRL-R ECD recognizes
two distinct binding interfaces on each of two different
hormones, yet each hormone activates a distinct biological
outcome. Exactly how this is accomplished is an area of
intense interest in both basic and applied research and
many unresolved molecular recognition issues remain.
We present, here, a methodology that utilizes a novel
class of affinity reagents generated by phage displayis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that can effectively differentiate between ligands that bind
to the same receptor epitope. These affinity reagents are
based on the antigen-antibody fragment (Fab) antibody
frameworks and are called “synthetic antibodies” or sABs
[7]. The extracellular domain of the human prolactin re-
ceptor (hPRL-R) was chosen as a target system because
of its number of activating hormones [5,6,8] and the
biological implications of being able to selectively tune
its activity [3,9,10]. Structural studies comparing the
two hormone-receptor complexes [4] suggested that
such selectivity could be achieved by capturing subtle
conformational differences induced by hGH versus hPRL
at either site in the ECD through an allosteric-control
mechanism.
To generate sABs against hPRL-R, the immobilized
ECD was incubated with a 1010 member reduced genetic
code phage display library [11]. The sABs are displayed
in bivalent format by fusion to the pIII coat protein of
M13 phage. Diversity is introduced into four of the six
complementary determining region (CDR) binding loops.
After three rounds of selection followed by a binding
screen by phage ELISA, four unique sAB clones were
identified. All four sABs, designated A4, A8, A9 and A10,
were expressed and purified, and their affinities for the
hPRL-R ECD were determined by surface plasmon reson-
ance (SPR) (Table 1). Three of the four sABs exhibited
nanomolar affinities for the hPRL-R ECD. sAB, A4
showed little detectable binding in a protein format and
thus was used as a negative control in the subsequent
experiments.
To gain insight into the structural basis of the interac-
tions between the sABs and hPRL-R, we determined the
crystal structure of the receptor in complex with sAB A8.
In the structure, the sAB binds to the opposite face of the
ECD away from the hormone-binding site (Figure 1a). In-
teractions between the two molecules are mediated by
side chain residues of the CDR loops of the sAB and the
hinge region that connects the two tandem fibronectin
(FN) domains of hPRL-R (Figure 1b). Alignment of the
ECD FN2 domain in the context of the sAB-bound struc-
ture with the 2:1 PRLR: PRL structure [8] reveals that the
sAB captures a hinge-bending conformation that resultsTable 1 Binding kinetics and loop sequence of PRL-R sABs
sAB kon (M




A-4 No binding HYT
A-8 9.6 × 104 5.4 × 10−4 5.6 YYS
A-9 1.4 × 104 3.4 × 10−5 2.5 YSS
A-10 1.2 × 105 2.6 × 10−3 21 HYT
aBinding kinetics were determined by SPR on a Biacore 2000, dissociation constant
bRandomized loops in the Fab scaffold, L3: light chain loop 3; H1, H2 and H3: heavyin a subtle, but significant rotation of FN1 relative to FN2
(Figure 1c).
Interestingly, the receptor in complex with the sAB
more closely resembles the hGH-bound form than the
PRL-bound form [4] (Figure 1d). By aligning the FN1
domains of all three structures, the FN2 of the sAB-bound
form and the hGH-bound form align well, while the FN2
of the PRL-bound is offset from the other 2 structures
(Figure 1d). This observation implies that the sAB would
have a greater impact on PRL binding than hGH binding.
To test this, we examined the ability of each hormone
to inhibit sAB binding to the receptor using a phage
ELISA. In this experiment, the biotinylated receptor
was immobilized on streptavidin plates and incubated
with increasing concentrations of either hGH or PRL
in the presence of phage displaying sAB A8, A9 or
A10. By detecting the relative amount of phage bound
to the receptor at each hormone concentration, IC50
values for each hormone-sAB combination were deter-
mined (Figure 1e). Although hGH has a higher affinity
for the receptor (Kd ~1nM) [6] than PRL (Kd ~6nM)
[2], the IC50 values for hGH were ~5 fold higher than
those for PRL (Figure 1f ). This indicates that PRL has a
more profound inhibitory effect on sAB-receptor inter-
action than hGH, an observation that is consistent with
structure alignments (Figure 1d). The results also sug-
gest that all three sABs bind to the same epitope on
the receptor, supported by basic epitope mapping using
phage ELISA (Additional file 1: Figure S2).
We note that biological signaling requires the hormones
to bind the ECD at both Site1 and the lower affinity Site2.
Thus, it is possible that the sABs have an even more pro-
found effect on ECD binding at Site2. Unfortunately, be-
cause of its more transient nature, it is not possible to
quantitatively measure the influence of sABs on binding
of the hormone at Site2. Thus, we instead quantified the
effects using relevant biological readouts of the intracellu-
lar signaling mechanism mediated by the hPRL-R using
T47D, a breast cancer cell-line. First, we examined the ef-
fects of sABs on hormone-induced receptor internaliza-
tion, which is a ubiquitous feature of cytokine receptor
activation. We tested the ability of the four sABs to block
hPRL-R-mediated internalization of cy5-labeled hPRL orp sequence
H1b H2b H3b
TPP FYSSYI YIYPSYGY SYYSYYGWDYHNSSGAM
YYYPF FSSSSM YISPYYGS SYGYVYWNAYSSGM
SYLL FSSSSI SIYSYYSS SYDSYPWVYSYTVSGAF
TPP FSSSYI SISPYYGS SYYYPEETAF
was calculated from the on and off rates.
chain loop 1, 2 and 3, respectively.
Figure 1 Crystal structure of the hPRL-R in complex with sAB A8. a sAB A8 (green) binds to the human PRL-R (red) opposite to the hormone
binding site. b A close up of the interactions between the CDR loops of sAB A8 (green) and the hinge region between the two fibronectin (FN)
domains of PRL-R (red). c Alignment of the FN2 domains of the PRL-R structure determined here (red) with the PRL-R structure (yellow) bound to
PRL (grey) in the 2:1 complex (PDB code: 3NPZ), the side view (above) shows the twist between the two FN domains induced by sAB binding
and the top view (below) shows a rotation of the FN1 domain relative to the FN2 domain in the sAB-bound structure. d Alignment of the sAB-
bound PRL-R (red) with the hGH-bound PRL-R (green) and the PRL-bound PRL-R (yellow) using the FN2. The bottom panel is a top view of the
FN1 of all three structures, with the sAB-bound receptor more resembling the hGH-bound conformation. e Inhibition of sAB binding by hGH or
PRL using phage ELISA. Both hGH (left panel) and PRL (right panel) inhibit the interaction between phage-displayed sABs and hPRL-R in a
concentration dependent manner. f IC50 values of the hGH or PRL inhibition of the interaction between sABs and hPRL-R calculated from e.
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A9 and A10 significantly decreased or completely
abolished the internalization of hPRL, whereas the
control sAB A4 had no effect on hormone internaliza-
tion (Figure 2a). In contrast, internalization of hGH
was only slightly inhibited by sABs A8, A9 and A10
(Figure 2b), presumably due to the ability of the sABs
to recognize the conformation differences between the
hPRL and hGH bound forms of hPRL-R.
We next examined the concentration and time-
dependent effects of the sABs on hPRL-R signaling. A
luciferase reporter assay [12] revealed that sABs A8,A9 and A10 exhibit a concentration-dependent inhibition
of downstream Stat5 phosphorylation, whereas the control
sAB A4 showed no significant effect (Figure 2c). The
inhibition of hPRL-R signaling by these three sABs was
confirmed by western blot analysis of the downstream
components of the prolactin induced signaling pathway
(Figure 2d). These sABs drastically inhibited Stat5 and
ERK phosphorylation, and partially inhibited AKT phos-
phorylation. Additionally, inhibition of signaling is cor-
related with the affinity of each sAB for the receptor.
The structural information gained from the A8-hPRL-R
complex reveals the mechanism by which the sAB
Figure 2 sAB inhibition of hPRL-R in T47D breast cancer cells. a-b Fluorescence microscopy images of cells treated with 100 nM cy5-hPRL (a) or
cy5-hGH (b) in the presence of each sAB. All panels represent two merged channels; blue: DAPI nuclear stain, red: cy5. c A Stat5 phospholyration
luciferase reporter assay of T47D cells in the presence or absence of hPRL and hPRL-R sABs. A sAB against bacterial maltose binding protein (MBP) [7]
was used as a negative control. d Western blot detection of the time-dependent inhibition of hPRL-R signaling by hPRL-R sABs.
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ability of a number of cytokine receptors, including hPRL-
R, to bind to multiple ligands, which manifest in different
biological responses, brings about important questions
relating subtle changes in receptor conformation on the
cell-surface to downstream effects inside the cell. Our
work indicates that sABs can distinguish between such
subtle differences in receptor structure, i.e. hGH-bound
vs. hPRL-bound, that ultimately define the function of the
receptor. Therefore, the ability to utilize phage display to
rationally engineer sophisticated reagents as highly select-
ive inhibitors with defined behavior can serve as a power-
ful approach to investigate the diversity of structural states
of cell-surface receptors and to design new drugs.
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